Compositions and methods of modulating short-chain dehydrogenase
US-2020095206-A1 · Mar 26, 2020 · US
15-PGDH inhibitors
US12304897B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12304897-B2 |
| Application number | US-202017310268-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2020 |
| Priority date | Jan 31, 2019 |
| Publication date | May 20, 2025 |
| Grant date | May 20, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of formula (1) or a pharmacologically acceptable salt thereof, wherein the formula (1) is selected from the group consisting of where G 1 is a phenyl group optionally having at least one substituent selected from group A, a 5-membered aromatic heterocyclic group optionally having at least one substituent selected from the group A, a 6-membered aromatic heterocyclic group optionally having at least one substituent selected from the group A, a bicyclic aromatic heterocyclic group having 8 to 10 atoms and optionally having at least one substituent selected from the group A, a fused heterocyclic group having 9 or 10 atoms and optionally having at least one substituent selected from the group A, C 3 -C 8 cycloalkyl group optionally having at least one substituent selected from the group A or 3 to 8-membered heterocycloalkyl group optionally having at least one substituent selected from the group A; R 3 and R 4 are each independently selected from hydrogen, halogen, —CN, —COOY, —NHC(O)Y, C 1 -C 6 alkyl optionally having at least one substituent selected from group C, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group C or C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group C; R 6 is hydrogen, halogen, —CN, —COOY, —NHC(O)Y, C, C 1 -C 6 alkyl optionally having at least one substituent selected from the group C, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group C or C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group C; R 7 and R 8 are each independently selected from hydrogen, halogen, —CN, —COOY, —NHC(O)Y, C 1 -C 6 alkyl optionally having at least one substituent selected from the group C, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group C or C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group C; R 10 is hydrogen, halogen, —CN, —COOY, —NHC(O)Y, C 1 -C 6 alkyl optionally having at least one substituent selected from the group C, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group C or C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group C; Y is independently selected from hydrogen, C 1 -C 6 alkyl optionally having at least one substituent selected from the group C, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group C or C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group C; the group A is halogen, hydroxyl, carbonyl, nitrile, carboxyl, formyl, C 1 -C 6 alkyl optionally having at least one substituent selected from group A1, C 1 -C 6 alkylcarbonyl optionally having at least one substituent selected from the group A1, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group A1, C 1 -C 6 alkoxycarbonyl optionally having at least one substituent selected from the group A1, C 1 -C 6 alkylsulfonyl optionally having at least one substituent selected from the group A1, C 1 -C 6 alkylsulfonylamino optionally having at least one substituent selected from the group A1, C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group A1, C 3 -C 8 cycloalkylcarbonyl optionally having at least one substituent selected from the group A1, C 3 -C 8 cycloalkoxy optionally having at least one substituent selected from the group A1, C 3 -C 8 cycloalkylsulfonyl optionally having at least one substituent selected from the group A1, C 3 -C 8 cycloalkylsulfonylamino optionally having at least one substituent selected from the group A1, C 5 -C 7 heterocycloalkyl optionally having at least one substituent selected from the group A1, C 5 -C 7 heterocycloalkylcarbonyl optionally having at least one substituent selected from the group A1, C 5 -C 7 heterocycloalkylamino optionally having at least one substituent selected from the group A1, C 5 -C 7 heterocycloalkylaminocarbonyl optionally having at least one substituent selected from the group A1, aminocarbonyl optionally substituted with one or two C 1 -C 6 alkyl optionally at least one having substituent selected from the group A1, aminosulfonyl optionally substituted with one or two C 1 -C 6 alkyl optionally having at least one substituent selected from the group A1, amino optionally substituted with one or two C 1 -C 6 alkyl optionally having at least one substituent selected from the group A1, phenyl optionally having at least one substituent selected from the group B, 5-membered aromatic heterocyclic group optionally having at least one substituent selected from the group B, 6-membered aromatic heterocyclic group optionally having at least one substituent selected from the group B or heterocyclic group optionally having substituent(s) selected from the group B; the group A1 is halogen, hydroxyl, amino, carbonyl, nitrile, carboxyl, formyl, C 1 -C 6 alkyl optionally having at least one substituent selected from group A2, C 1 -C 6 alkylcarbonyl optionally having at least one substituent selected from the group A2, C 1 -C 6 alkoxy optionally having at least one substituent selected from the group A2, C 1 -C 6 alkoxycarbonyl optionally having at least one substituent selected from the group A2, C 1 -C 6 alkylsulfonyl optionally having at least one substituent selected from the group A2, C 1 -C 6 alkylsulfonylamino optionally having at least one substituent selected from the group A2, C 3 -C 8 cycloalkyl optionally having at least one substituent selected from the group A2, C 5 -C 7 heterocycloalkyl optionally having at least one substituent selected from the group A2, C 5 -C 7 heterocycloalkylcarbonyl optionally having at least one substituent selected from the group A2, C 5 -C 7 heterocycloalkylamino optionally having at least one substituent selected from the group A2, C 5 -C 7 heterocycloalkylaminocarbonyl optionally having at least one substituent selected from the group A2, aminocarbonyl optionally substituted with one or two C 1 -C 6 alkyl optionally having at least one substituent selected from the group A2, amino optionally substituted with one or two C 1 -C 6 alkyl optionally having at least one substituent selected from the group A2, 5-membered aromatic heterocyclic group optionally having at least one substituent selected from the group B, 6-membered aromatic heterocyclic group optionally having at least one substituent selected from the group B or heterocyclic group optionally having at least one substituent selected from the group B; the group A2 is halogen, hydroxyl, nitrile, carboxyl, formyl, C 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkylsulfonylamino, 5-membered aromatic heterocyclic group, 6-membered aromatic heterocyclic group, heterocyclic group or 5 to 7-membered heterocycloalkyl group; the group B is halogen, hydroxyl, carbonyl, carboxyl, C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, hydroxy-C 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxy, C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkoxy, aminocarbonyl optionally substituted with one or two C 1 -C 6 alkyl, C 1 -C 6 alkylsulfonyl, aminosulfonyl optionally substituted with one or two C 1 -C 6 alkyl, C 1 -C 6 alkylsulfonylamino, amino optionally substituted with one or two C 1 -C 6 alkyl or 5 to 7-membered heterocycloalkyl group; the group C is halogen, hydroxyl, carboxyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, aminocarbonyl optionally substituted with one or two C 1 -C 6 alkyl, amino
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
Spiro-condensed systems · CPC title
Ortho-condensed systems · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12304897B2 cover?
- A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.
- Who is the assignee on this patent?
- Kyorin Seiyaku Kk
- What technology area does this patent fall under?
- Primary CPC classification C07D401/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).